| BUSINESSWEEK ONLINE : FEBRUARY 22, 1999 ISSUE | ||||||||
| ||||||||
 | ||||||||
| READERS REPORT
Xalatan: An Rx for Fewer Doctor Visits ''When an ounce of prevention costs too much'' (News: Analysis & Commentary, Jan. 25) misses several points, based on my experience. You cite Kaiser Permanente's costs of prescribing Xalatan for glaucoma. I am one of those patients. The generic beta blocker I tried for ocular pressure did not work, and I saw my ophthalmologist up to four times per year. With Xalatan, we will be down to one visit per year. So, drug costs are clearly up, but the total cost of treatment--where is that accounting category?--is surely down. R.L. Promboin Westlake Village, Calif. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ |
|  |
 | |
INTERACT E-Mail to Business Week Online | |||
